These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 17134969)
1. Bortezomib induces different apoptotic rates in B-CLL cells according to IgVH and BCL-6 mutations. Jantus-Lewintre E; Sarsotti E; Terol MJ; Benet I; García-Conde J Clin Transl Oncol; 2006 Nov; 8(11):805-11. PubMed ID: 17134969 [TBL] [Abstract][Full Text] [Related]
2. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Wiestner A; Rosenwald A; Barry TS; Wright G; Davis RE; Henrickson SE; Zhao H; Ibbotson RE; Orchard JA; Davis Z; Stetler-Stevenson M; Raffeld M; Arthur DC; Marti GE; Wilson WH; Hamblin TJ; Oscier DG; Staudt LM Blood; 2003 Jun; 101(12):4944-51. PubMed ID: 12595313 [TBL] [Abstract][Full Text] [Related]
3. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. Crespo M; Bosch F; Villamor N; Bellosillo B; Colomer D; Rozman M; Marcé S; López-Guillermo A; Campo E; Montserrat E N Engl J Med; 2003 May; 348(18):1764-75. PubMed ID: 12724482 [TBL] [Abstract][Full Text] [Related]
4. Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma. Bu R; Hussain AR; Al-Obaisi KA; Ahmed M; Uddin S; Al-Kuraya KS Leuk Lymphoma; 2014 Feb; 55(2):415-24. PubMed ID: 23697845 [TBL] [Abstract][Full Text] [Related]
5. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464 [TBL] [Abstract][Full Text] [Related]
6. Expression of ZAP-70 protein correlates with disease stage in chronic lymphocytic leukemia and is associated with, but not generally restricted to, non-mutated Ig VH status. Kim SZ; Chow KU; Kukoc-Zivojnov N; Boehrer S; Brieger A; Steimle-Grauer SA; Harder L; Hoelzer D; Mitrou PS; Weidmann E Leuk Lymphoma; 2004 Oct; 45(10):2037-45. PubMed ID: 15370248 [TBL] [Abstract][Full Text] [Related]
7. The prognostic evaluation of CLLU1 expression levels in 50 Chinese patients with chronic lymphocytic leukemia. Chen L; Li J; Zheng W; Zhang Y; Wu Y; Li L; Qian S; Xu W Leuk Lymphoma; 2007 Sep; 48(9):1785-92. PubMed ID: 17786715 [TBL] [Abstract][Full Text] [Related]
8. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells. Kabore AF; Sun J; Hu X; McCrea K; Johnston JB; Gibson SB Apoptosis; 2006 Jul; 11(7):1175-93. PubMed ID: 16699949 [TBL] [Abstract][Full Text] [Related]
10. Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes. Campàs C; Lopez JM; Santidrián AF; Barragán M; Bellosillo B; Colomer D; Gil J Blood; 2003 May; 101(9):3674-80. PubMed ID: 12522004 [TBL] [Abstract][Full Text] [Related]
11. Drug-induced apoptosis in chronic lymphocytic leukemia. Stoetzer OJ; Pogrebniak A; Scholz M; Pelka-Fleischer R; Gullis E; Darsow M; Nüssler V; Wilmanns W Leukemia; 1999 Nov; 13(11):1873-80. PubMed ID: 10557065 [TBL] [Abstract][Full Text] [Related]
12. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. Dai Y; Chen S; Kramer LB; Funk VL; Dent P; Grant S Clin Cancer Res; 2008 Jan; 14(2):549-58. PubMed ID: 18223231 [TBL] [Abstract][Full Text] [Related]
14. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Byrd JC; Shinn C; Waselenko JK; Fuchs EJ; Lehman TA; Nguyen PL; Flinn IW; Diehl LF; Sausville E; Grever MR Blood; 1998 Nov; 92(10):3804-16. PubMed ID: 9808574 [TBL] [Abstract][Full Text] [Related]
15. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma. Gu JJ; Hernandez-Ilizaliturri FJ; Kaufman GP; Czuczman NM; Mavis C; Skitzki JJ; Czuczman MS Br J Haematol; 2013 Sep; 162(5):657-69. PubMed ID: 23826755 [TBL] [Abstract][Full Text] [Related]
16. CLLU1 expression levels predict time to initiation of therapy and overall survival in chronic lymphocytic leukemia. Buhl AM; Jurlander J; Geisler CH; Pedersen LB; Andersen MK; Josefsson P; Petersen JH; Leffers H Eur J Haematol; 2006 Jun; 76(6):455-64. PubMed ID: 16529606 [TBL] [Abstract][Full Text] [Related]
17. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Pahler JC; Ruiz S; Niemer I; Calvert LR; Andreeff M; Keating M; Faderl S; McConkey DJ Clin Cancer Res; 2003 Oct; 9(12):4570-7. PubMed ID: 14555532 [TBL] [Abstract][Full Text] [Related]
18. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities. Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668 [TBL] [Abstract][Full Text] [Related]
19. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Gatto S; Scappini B; Pham L; Onida F; Milella M; Ball G; Ricci C; Divoky V; Verstovsek S; Kantarjian HM; Keating MJ; Cortes-Franco JE; Beran M Haematologica; 2003 Aug; 88(8):853-63. PubMed ID: 12935973 [TBL] [Abstract][Full Text] [Related]
20. Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-ĸB signaling, and synergizes with an ERK inhibitor. Yang F; Jove V; Chang S; Hedvat M; Liu L; Buettner R; Tian Y; Scuto A; Wen W; Yip ML; Van Meter T; Yen Y; Jove R Cancer Biol Ther; 2012 Apr; 13(6):349-57. PubMed ID: 22313636 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]